Advertisement

ERRATUM

In the article by Greenberg et al, entitled “International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes,” which appeared in the March 15, 1997 (Vol 89, No 6, pp 2079-2088) issue, a correction should be noted. In the text p 2080 and in Table 1, neutropenia (absolute neutrophil count, ANC) was inadvertently and incorrectly stated as being defined as <1,500/μL rather than <1,800/μL. The latter number (<1,800/μL) was used to define this cytopenia for the risk scoring indicated in Table 3 and for generating the International Prognostic Scoring System (IPSS) risk groups. As some readers may utilize the number 1,500/μL for their classification of neutropenia, we recalculated the impact of this error on our own data and demonstrated that this change was clinically and statistically insignificant. If this number (1,500/μL) had been used, only 8 patients (of 816 patients, 1%) would have needed reclassification for Survival and 7 (of 759 patients) reclassified for AML evolution. All of the reclassified patients would have been changed from either the Intermediate-2 or -1 categories into the Low-Risk group, as fewer patients would have been defined as being neutropenic. The median survival and AML evolution times and Kaplan-Meier curves were essentially unaltered when using this changed value. Readers should be aware of this correction and use the <1,800/μL cutpoint for categorizing MDS patients according to the IPSS.